Experiments performed in the BLIS laboratories allowed me to investigate whether these S. salivarius megaplasmids are required for production of BLIS active against pneumococci. I became competent in the technique of deferred antagonism testing, analysing the BLIS activity of 10 Streptococcus salivarius strains against pneumococcal isolates shipped to New Zealand from our laboratory for this purpose.
My results showed S. salivarius strains harbouring known salivaricins all produced BLIS capable of inhibiting the growth of all pneumococcal isolates tested, suggesting salivaricins are required for in vitro BLIS activity against pneumococci.
K12 and M18 megaplasmid-negative strains did not produce BLIS activity against pneumococci ( Fig. 1 ), suggesting these megaplasmids mediate BLIS production in these strains, likely due to their encoded salivaricins. Briefly, S. salivarius strains were inoculated vertically on human blood agar plates, culture was removed following overnight incubation and plates were treated with chloroform. Pneumococcal isolates were then inoculated horizontally across the plate and incubated overnight. Inhibition of pneumococcal growth in the area where the S. salivarius inoculum was present was interpreted as the S. salivarius strain producing BLIS active against the pneumococci. Jayne Manning with Professor John Tagg. The Master Class program consisted of a full day of interactive seminars with a second day devoted to a hands-on wet workshop. During the seminar program Lynne presented a range of topics related to diagnostic parasitology. In the opening sessions she discussed the importance of
